Reuters logo
7 months ago
BRIEF-Genentech withdraws counterclaim against Exelixis in JAMS arbitration
January 9, 2017 / 10:19 AM / 7 months ago

BRIEF-Genentech withdraws counterclaim against Exelixis in JAMS arbitration

Jan 9 (Reuters) - Exelixis Inc :

* Update on dispute between Exelixis and Genentech, a member of the Roche group

* Exelixis relieved of $18.7 million of disputed costs

* Genentech withdrew counterclaim against company in ongoing JAMS arbitration concerning "alleged breaches of parties' collaboration agreement"

* Genentech's action does not address claims related to its clinical development, pricing and promotional costs for COTELLIC in United States

* Genentech has not confirmed how it will allocate promotional costs with respect to collaboration's promotion of other combination therapies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below